Seres Therapeutics (MCRB) Other financing activities (2017 - 2026)
Seres Therapeutics (MCRB) posted Other financing activities of $28000.0 for Q1 2026, down 89.67% sequentially from $271000.0 in Q4 2025, and down 84.78% YoY from $184000.0 in Q1 2025.
Seres Therapeutics (MCRB) Other financing activities (2017 - 2026) Analysis & Trends
Seres Therapeutics has reported Other financing activities for 10 years, with the latest figure at $28000.0 in Q1 2026.
- Quarterly Other financing activities fell 84.78% year-over-year to $28000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $345000.0 (up 304.14% YoY) and the FY2025 annual result came in at $501000.0, changed N/A from the prior year.
- Other financing activities declined to $28000.0 in Q1 2026 per MCRB's latest filing, from $271000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $1.8 million in Q3 2023 and troughed at -$1.3 million in Q4 2023.
- A 5-year average of $244230.8 and a median of $184000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2023: Other financing activities soared 1163.08% in 2022, then plunged 771.54% in 2023.
- Over 5 years, Other financing activities stood at $1.4 million in 2022, then sank by 192.19% to -$1.3 million in 2023, then jumped by 72.29% to -$353000.0 in 2024, then surged by 176.77% to $271000.0 in 2025, then slumped by 89.67% to $28000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $28000.0, $271000.0, and $46000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28,000.00 |
| Mar 31, 2026 | 28,000.00 |
| Dec 31, 2025 | 271,000.00 |
| Dec 31, 2025 | 271,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 184,000.00 |
| Mar 31, 2025 | 184,000.00 |
| Sep 30, 2024 | -353,000.00 |
| Sep 30, 2024 | -353,000.00 |
| Mar 31, 2024 | 353,000.00 |
| Mar 31, 2024 | 353,000.00 |
| Dec 31, 2023 | -1.27 Mn |
| Dec 31, 2023 | -1.27 Mn |
| Sep 30, 2023 | 1.80 Mn |
| Sep 30, 2023 | 1.80 Mn |
| Jun 30, 2023 | -873,000.00 |
| Jun 30, 2023 | -873,000.00 |
| Mar 31, 2023 | 1.23 Mn |
| Mar 31, 2023 | 1.23 Mn |